Cargando…

Dornase alpha use in patients with cystic fibrosis

Detalles Bibliográficos
Autor principal:	Marostica, Paulo José C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade de Pediatria de São Paulo 2013
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183042/ https://www.ncbi.nlm.nih.gov/pubmed/24473944 http://dx.doi.org/10.1590/S0103-05822013000400001

Ejemplares similares

Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index
por: Terlizzi, Vito, et al.
Publicado: (2022)

A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study
por: Rozov, Tatiana, et al.
Publicado: (2013)

The use of dornase alfa in patients with COVID-19
por: Ramachandram, Dinesh Sangarran, et al.
Publicado: (2023)

Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series
por: Terlizzi, Vito, et al.
Publicado: (2022)

Variation in lung function is associated with worse clinical outcomes in cystic fibrosis
por: Heinzmann-Filho, João Paulo, et al.
Publicado: (2015)

Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers
por: Chang, Kyung Hwa, et al.
Publicado: (2020)

Microbiological contamination of nebulizers used by cystic fibrosis patients: an underestimated problem
por: Riquena, Barbara, et al.
Publicado: (2019)

USE OF ALTEPLASE AND DORNASE FOR LYSIS OF COVID-19-RELATED LOCULATED PLEURAL EFFUSION
por: STAIANO, PETER P, et al.
Publicado: (2022)

Incidence and treatment of methicillin-resistant S. aureus infection in cystic fibrosis patients: a cohort study
por: Bittencourt, Paloma Horejs, et al.
Publicado: (2016)

The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
por: Toma, Andrew, et al.
Publicado: (2021)

THE USE OF ULTRASONOGRAPHY TO EVALUATE MUSCLE THICKNESS AND SUBCUTANEOUS FAT IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS
por: de Souza, Rodrigo Pereira, et al.
Publicado: (2018)

Can the data of microbiome be used to predict the presence of Burkholderia spp in pulmonary microbiota of cystic fibrosis patients?
por: Volpato, Fabiana Caroline Zempulski, et al.
Publicado: (2023)

BODY MASS INDEX AND ALBUMIN LEVELS ARE ASSOCIATED WITH PULMONARY FUNCTION PARAMETERS IN PEDIATRIC SUBJECTS WITH CYSTIC FIBROSIS
por: Simon, Miriam Isabel Souza dos Santos, et al.
Publicado: (2019)

Cystic fibrosis revisited
por: Kulkarni, H, et al.
Publicado: (2019)

Ultrasound findings of pubertal development in girls with cystic fibrosis and their association with clinical outcomes and Tanner staging
por: Lopes, Paula de Souza Dias, et al.
Publicado: (2021)

Early Antibiotics in Cystic Fibrosis: Lessons from the Cystic Fibrosis Pig Model
por: Lu, Shiping, et al.
Publicado: (2021)

Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in the Cystic Fibrosis Registry
por: Thompson, Cassandra, et al.
Publicado: (2023)

High-risk twin pregnancy: case report of an adolescent patient with cystic fibrosis and systemic lupus erythematosus
por: Sanseverino, Paula Baptista, et al.
Publicado: (2022)

Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
por: Earhart, A.P., et al.
Publicado: (2020)

Preliminary report of in vitro and in vivo effectiveness of dornase alfa on SARS-CoV-2 infection
por: Okur, H.K., et al.
Publicado: (2020)

Association between hypovitaminosis D and frequency of pulmonary exacerbations in children and adolescents with cystic fibrosis
por: Ongaratto, Renata, et al.
Publicado: (2018)

Clinical Advances in Cystic Fibrosis
por: Imperlini, Esther, et al.
Publicado: (2022)

Cystic Fibrosis: “Ionocyte Modulators”?
por: Shah, Viral S., et al.
Publicado: (2023)

The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
por: Maetz, Jessica, et al.
Publicado: (2021)

A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants
por: Wainwright, Claire E.
Publicado: (2022)

Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19
por: Holliday, Zachary M., et al.
Publicado: (2021)

Use of dornase alfa in the paediatric intensive care unit: current literature and a national cross-sectional survey
por: den Hollander, Bibiche, et al.
Publicado: (2022)

Cystic fibrosis in Brazil: achievements in survival
por: Vendrusculo, Fernanda Maria, et al.
Publicado: (2021)

The Impact of COVID-19 in Cystic Fibrosis
por: Flume, Patrick A., et al.
Publicado: (2022)

Comparing cystic fibrosis outcomes across the pond
por: Taylor-Robinson, David C, et al.
Publicado: (2015)

Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing
por: Hoppe, Jordana E., et al.
Publicado: (2022)

New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Steps toward Cell Therapy for Cystic Fibrosis
por: Koh, Kyung Duk, et al.
Publicado: (2020)

Cystic fibrosis-related diabetes: The unmet need
por: Pozo, Leonardo, et al.
Publicado: (2020)

Preclinical Modeling for Therapeutic Development in Cystic Fibrosis
por: Bonfield, Tracey L.
Publicado: (2020)

Cystic Fibrosis Inflammation: Hyperinflammatory, Hypoinflammatory, or Both?
por: Murphy, Sean V., et al.
Publicado: (2019)

Where Is the Cystic Fibrosis Transmembrane Conductance Regulator?
por: Barbry, Pascal, et al.
Publicado: (2021)

Brazilian guidelines for the diagnosis and treatment of cystic fibrosis
por: Athanazio, Rodrigo Abensur, et al.
Publicado: (2017)

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series
por: Weber, Andrew G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q0iriaa7h1128j6gibk8l3gc98